SH2 domains: how docking modules reshape signaling and immune control in the 2020s
🧪 lmctl-orchestrated review — written by an orchestrated team of AI agents, grounded in 2,478 papers from lmmol's literature graph. Citations link to their source on PubMed.
| Protein | Papers |
|---|---|
| Growth factor receptor-bound protein 2 | 101 |
| Proto-oncogene tyrosine-protein kinase Src | 87 |
| Tyrosine-protein kinase BTK | 84 |
| Tyrosine-protein kinase ABL1 | 76 |
| Signal transducer and activator of transcription 3 | 76 |
| Tyrosine-protein phosphatase non-receptor type 11 | 75 |
| Signal transducer and activator of transcription 1-alpha/beta | 74 |
| Phosphatidylinositol 3-kinase regulatory subunit alpha | 74 |
1. Overview
The SH2 domain family (Pfam PF00017) remains the central docking logic for phosphotyrosine signaling, linking activated kinases to adaptors, phosphatases, and transcriptional switches. Because SH2 modules read short pY motifs with high context sensitivity, they encode both wiring specificity and competition pressure across pathways. Classic descriptions of Src-family and FGFR signaling still set the frame for how these interactions are staged at the membrane and propagate downstream signaling [1][2]. Over the last few years, the same module logic has become a platform for immune checkpoint biology, transcription factor tuning, and viral immune escape, all while retaining the same biophysical grammar [3][4].
2. Key proteins
This family is best anchored by a few high-depth proteins in lmmol: GRB2 (P62993) as canonical adapter logic, SRC (P12931), BTK (Q06187), ABL1 (P00519), STAT3 (P40763), PTPN11 (Q06124), STAT1 (P42224), and the PI3K alpha regulatory node (P27986). Together they span the classic upstream-to-transcription axis and show why SH2 remains dominant in both kinase-rich oncologic programs and cytokine-regulatory circuits.
3. Structural and mechanistic foundation
Three themes define the SH2 discipline: phosphotyrosine readout, site competition, and catalytic coupling via partner choice. The historical literature on Src-family architecture and FGFR signaling still captures this architecture, where one phosphosite can route to multiple outcomes depending on domain occupancy and dwell time [1][2]. Genetic disruption work on SHP-2 (PTPN11) reinforced how SH2-mediated recruitment shapes receptor-to-MAPK coupling and how point-level perturbations amplify into developmental disease [5].
4. What is new recently
A current trend is SH2 biology’s move beyond canonical kinase cascades into transcription and immune-regulation layers. Nuclear STAT biology and STAT epigenetic coupling are now described as dual-control systems where STAT phosphorylation state and cofactor context jointly gate inflammatory gene expression [6][7]. Therapeutic immunology has also exposed new SH2-centric mechanisms: PD-1 ITSM-driven SHP-2 activation appears to involve domain pairing and induced dimerization, adding a regulatory geometry layer to checkpoint signaling [4]. In parallel, immune-pathway studies connect SH2-dependent signaling to lymphocyte dysfunction and hyperinflammatory syndromes, including SOCS1 and SHP-2 axis perturbations [8][9].
5. From infection to cancer biology
Viral and innate systems now repeatedly exploit or modulate SH2-adjacent signaling with direct translational relevance. A notable example is ASFV MGF360-9L as a viral antagonist of JAK/STAT signaling, showing that pathogen pressure still selects for SH2-sensitive checkpoints [10]. Tumor contexts are adding further nuance: PD-L1-driven Gasdermin-C responses can rewire cell-death and inflammasome crosstalk, while STAT family regulation remains central to cytokine balance in malignancy and autoimmunity [3].
6. Outlook
For a class once treated as a largely static interaction module, SH2 biology is now best viewed as a dynamic interface competition problem: same fold, many contexts. The most likely near-term frontier is not a redesign of the domain itself, but improved, motif-aware perturbation models that can predict whether a given mutation, splice form, or allosteric drug state shifts the SH2-enabled signal map toward proliferation, tolerance, or inflammation.
References
- Thomas S.M., Brugge J.S. Cellular functions regulated by Src family kinases. Annu. Rev. Cell Dev. Biol 1997. PubMed 2,134×
- Eswarakumar V.P., Lax I., Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 2005. PubMed 1,530×
- Hou J., Zhao R., Xia W., Chang C.W. et al. PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosis. Nat. Cell Biol 2020. PubMed 785×
- Patsoukis N., Duke-Cohan J.S., Chaudhri A., Aksoylar H.I. et al. Interaction of SHP-2 SH2 domains with PD-1 ITSM induces PD-1 dimerization and SHP-2 activation. Commun. Biol 2020. PubMed 146×
- Tartaglia M., Mehler E.L., Goldberg R., Zampino G. et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat. Genet 2001. PubMed 1,281×
- Arimoto K.I., Loechte S., Stoner S.A., Burkart C. et al. STAT2 is an essential adaptor in USP18-mediated suppression of type I interferon signaling. Nat. Struct. Mol. Biol 2017. PubMed 156×
- Chen K., Liu J., Liu S., Xia M. et al. Methyltransferase SETD2-mediated methylation of STAT1 is critical for interferon antiviral activity. Cell 2017. PubMed 242×
- Hadjadj J., Castro C.N., Tusseau M., Stolzenberg M.C. et al. Early-onset autoimmunity associated with SOCS1 haploinsufficiency. Nat. Commun 2020. PubMed 125×
- Lee P.Y., Platt C.D., Weeks S., Grace R.F. et al. Immune dysregulation and multisystem inflammatory syndrome in children (MIS-C) in individuals with haploinsufficiency of SOCS1. J. Allergy Clin. Immunol 2020. PubMed 126×
- Zhang K., Yang B., Shen C., Zhang T. et al. MGF360-9L Is a Major Virulence Factor Associated with the African Swine Fever Virus by Antagonizing the JAK/STAT Signaling Pathway. MBio 2022. PubMed 96×